Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2019

May 15, 2019

32254_dirs_2019-05-15_77d3dcc6-6373-413c-b51d-a9925711b1b5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2019-05-13

Reporting Person: Landis John B. (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-05-13 Common Stock P 40000.00 $1.74 Acquired 40000.00 Direct